Literature DB >> 20549206

Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners.

Xinmei Zhu1, Beth A Fallert-Junecko, Mitsugu Fujita, Ryo Ueda, Gary Kohanbash, Edward R Kastenhuber, Heather A McDonald, Yan Liu, Pawel Kalinski, Todd A Reinhart, Andres M Salazar, Hideho Okada.   

Abstract

Stimulation of double-stranded (ds)RNA receptors can increase the effectiveness of cancer vaccines, but the underlying mechanisms are not completely elucidated. In this study, we sought to determine critical roles of host IFN-alpha and IFN-gamma pathways in the enhanced therapeutic efficacy mediated by peptide vaccines and polyinosinic-polycytidylic acid [poly(I:C)] stabilized by lysine and carboxymethylcellulose (poly-ICLC) in the murine central nervous system (CNS) GL261 glioma. C57BL/6-background wild type (WT), IFN-alpha receptor-1 (IFN-alphaR1)(-/-) or IFN-gamma(-/-) mice bearing syngeneic CNS GL261 glioma received subcutaneous (s.c.) vaccinations with synthetic peptides encoding CTL epitopes with or without intramuscular (i.m.) injections of poly-ICLC. The combinational treatment induced a robust transcription of CXCL10 in the glioma site. Blockade of CXCL10 with a specific monoclonal antibody (mAb) abrogated the efficient CNS homing of antigen-specific type-1 CTL (Tc1). Both IFN-alphaR(-/-) and IFN-gamma(-/-) hosts failed to up-regulate the CXCL10 mRNA and recruit Tc1 cells to the tumor site, indicating non-redundant roles of type-1 and type-2 IFNs in the effects of poly-ICLC-assisted vaccines. The efficient trafficking of Tc1 also required Tc1-derived IFN-gamma. Our data point to critical roles of the host-IFN-alpha and IFN-gamma pathways in the modulation of CNS glioma microenvironment, and the therapeutic effectiveness of poly-ICLC-assisted glioma vaccines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20549206      PMCID: PMC2893267          DOI: 10.1007/s00262-010-0876-3

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  52 in total

1.  Induction of the chemokine receptor CXCR3 on TCR-stimulated T cells: dependence on the release from persistent TCR-triggering and requirement for IFN-gamma stimulation.

Authors:  Chigusa Nakajima; Takao Mukai; Nobuya Yamaguchi; Yasunari Morimoto; Woong-Ryeon Park; Masayuki Iwasaki; Ping Gao; Shiro Ono; Hiromi Fujiwara; Toshiyuki Hamaoka
Journal:  Eur J Immunol       Date:  2002-06       Impact factor: 5.532

2.  Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine.

Authors:  Yukihiko Iizuka; Hidefumi Kojima; Tetsuji Kobata; Takeshi Kawase; Yutaka Kawakami; Masahiro Toda
Journal:  Int J Cancer       Date:  2006-02-15       Impact factor: 7.396

3.  Requirement of the IFN-alpha/beta-induced CXCR3 chemokine signalling for CD8+ T cell activation.

Authors:  Kouetsu Ogasawara; Shigeaki Hida; Youmin Weng; Akio Saiura; Kojiro Sato; Hiroshi Takayanagi; Shinya Sakaguchi; Taeko Yokochi; Tatsuhiko Kodama; Makoto Naitoh; Julie A De Martino; Tadatsugu Taniguchi
Journal:  Genes Cells       Date:  2002-03       Impact factor: 1.891

4.  Preferential expression and function of Toll-like receptor 3 in human astrocytes.

Authors:  Cinthia Farina; Markus Krumbholz; Thomas Giese; Gunther Hartmann; Francesca Aloisi; Edgar Meinl
Journal:  J Neuroimmunol       Date:  2004-11-11       Impact factor: 3.478

5.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

6.  Inhibition of indoleamine 2,3-dioxygenase activity in IFN-gamma stimulated astroglioma cells decreases intracellular NAD levels.

Authors:  Ross Grant; Vimal Kapoor
Journal:  Biochem Pharmacol       Date:  2003-09-15       Impact factor: 5.858

7.  The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine.

Authors:  Christine Trumpfheller; Marina Caskey; Godwin Nchinda; Maria Paula Longhi; Olga Mizenina; Yaoxing Huang; Sarah J Schlesinger; Marco Colonna; Ralph M Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-06       Impact factor: 11.205

8.  Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.

Authors:  Mitsugu Fujita; Xinmei Zhu; Ryo Ueda; Kotaro Sasaki; Gary Kohanbash; Edward R Kastenhuber; Heather A McDonald; Gregory A Gibson; Simon C Watkins; Ravikumar Muthuswamy; Pawel Kalinski; Hideho Okada
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

9.  Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function.

Authors:  Robbie B Mailliard; Young-Ik Son; Richard Redlinger; Patrick T Coates; Adam Giermasz; Penelope A Morel; Walter J Storkus; Pawel Kalinski
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.426

10.  Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors.

Authors:  Manabu Hatano; Naruo Kuwashima; Tomohide Tatsumi; Jill E Dusak; Fumihiko Nishimura; Karlyne M Reilly; Walter J Storkus; Hideho Okada
Journal:  J Transl Med       Date:  2004-11-24       Impact factor: 5.531

View more
  48 in total

Review 1.  The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

Authors:  Craig L Slingluff
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.

Authors:  Chrisann Kyi; Vladimir Roudko; Rachel Sabado; Yvonne Saenger; William Loging; John Mandeli; Tin Htwe Thin; Deborah Lehrer; Michael Donovan; Marshall Posner; Krzysztof Misiukiewicz; Benjamin Greenbaum; Andres Salazar; Philip Friedlander; Nina Bhardwaj
Journal:  Clin Cancer Res       Date:  2018-06-27       Impact factor: 12.531

Review 3.  Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses.

Authors:  Man Yu; Stewart J Levine
Journal:  Cytokine Growth Factor Rev       Date:  2011-04-03       Impact factor: 7.638

4.  Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.

Authors:  Gary Kohanbash; Diego A Carrera; Shruti Shrivastav; Brian J Ahn; Naznin Jahan; Tali Mazor; Zinal S Chheda; Kira M Downey; Payal B Watchmaker; Casey Beppler; Rolf Warta; Nduka A Amankulor; Christel Herold-Mende; Joseph F Costello; Hideho Okada
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

5.  Integration of epidemiology, immunobiology, and translational research for brain tumors.

Authors:  Hideho Okada; Michael E Scheurer; Saumendra N Sarkar; Melissa L Bondy
Journal:  Ann N Y Acad Sci       Date:  2013-05       Impact factor: 5.691

Review 6.  Prioritization schema for immunotherapy clinical trials in glioblastoma.

Authors:  Tiffany R Hodges; Sherise D Ferguson; Hillary G Caruso; Gary Kohanbash; Shouhao Zhou; Timothy F Cloughesy; Mitchel S Berger; George H Poste; Mustafa Khasraw; Sujuan Ba; Tao Jiang; Tom Mikkelson; W K Alfred Yung; John F de Groot; Howard Fine; Lewis C Cantley; Ingo K Mellinghoff; Duane A Mitchell; Hideho Okada; Amy B Heimberger
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

7.  Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.

Authors:  Jorrit De Waele; Elly Marcq; Jonas Rm Van Audenaerde; Jinthe Van Loenhout; Christophe Deben; Karen Zwaenepoel; Erik Van de Kelft; David Van der Planken; Tomas Menovsky; Johan Mj Van den Bergh; Yannick Willemen; Patrick Pauwels; Zwi N Berneman; Filip Lardon; Marc Peeters; An Wouters; Evelien Lj Smits
Journal:  Oncoimmunology       Date:  2017-12-12       Impact factor: 8.110

Review 8.  Effective effectors: How T cells access and infiltrate the central nervous system.

Authors:  Kendra L Congdon; Luis A Sanchez-Perez; John H Sampson
Journal:  Pharmacol Ther       Date:  2018-12-14       Impact factor: 12.310

9.  Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.

Authors:  Ileana S Mauldin; Nolan A Wages; Anne M Stowman; Ena Wang; Mark E Smolkin; Walter C Olson; Donna H Deacon; Kelly T Smith; Nadedja V Galeassi; Kimberly A Chianese-Bullock; Lynn T Dengel; Francesco M Marincola; Gina R Petroni; David W Mullins; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2016-08-13       Impact factor: 6.968

10.  Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.

Authors:  Ian F Pollack; Regina I Jakacki; Lisa H Butterfield; Ronald L Hamilton; Ashok Panigrahy; Daniel P Normolle; Angela K Connelly; Sharon Dibridge; Gary Mason; Theresa L Whiteside; Hideho Okada
Journal:  J Neurooncol       Date:  2016-09-13       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.